B
Brian W. Brannigan
Researcher at Harvard University
Publications - 27
Citations - 20131
Brian W. Brannigan is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Epidermal growth factor receptor. The author has an hindex of 22, co-authored 27 publications receiving 18682 citations.
Papers
More filters
Journal ArticleDOI
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Journal ArticleDOI
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
Nicola Aceto,Aditya Bardia,David T. Miyamoto,Maria C. Donaldson,Ben S. Wittner,Joel A. Spencer,Min Yu,Adam Pely,Amanda Engstrom,Huili Zhu,Brian W. Brannigan,Ravi Kapur,Shannon L. Stott,Toshi Shioda,Sridhar Ramaswamy,David T. Ting,Charles P. Lin,Mehmet Toner,Daniel A. Haber,Daniel A. Haber,Shyamala Maheswaran +20 more
TL;DR: Using mouse models with tagged mammary tumors, it is demonstrated that CTC clusters arise from oligoclonal tumor cell groupings and not from intravascular aggregation events, and though rare in the circulation, they greatly contribute to the metastatic spread of cancer.
Journal ArticleDOI
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Shyamala Maheswaran,Lecia V. Sequist,Sunitha Nagrath,Lindsey Ulkus,Brian W. Brannigan,Chey V. Collura,Elizabeth J. Inserra,Sven Diederichs,A. John Iafrate,Daphne W. Bell,Subba R. Digumarthy,Alona Muzikansky,Alona Muzikansky,Daniel Irimia,Jeffrey Settleman,Ronald G. Tompkins,Ronald G. Tompkins,Thomas J. Lynch,Mehmet Toner,Mehmet Toner,Daniel A. Haber,Daniel A. Haber +21 more
TL;DR: Molecular analysis of circulating tumor cells from the blood of patients with lung cancer offers the possibility of monitoring changes in epithelial tumor genotypes during the course of treatment, and shows that a reduction in the number of captured cells was associated with a radiographic tumor response; an increase in theNumber of cells wasassociated with tumor progression, with the emergence of additional EGFR mutations in some cases.
Journal ArticleDOI
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak Eunice L,Raffaella Sordella,Daphne W. Bell,Godin-Heymann Nadia G,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,David R. Driscoll,Panos Fidias,Thomas J. Lynch,Sridhar K. Rabindran,John P. McGinnis,Allan Wissner,Sreenath V. Sharma,Kurt J. Isselbacher,Jeffrey Settleman,Daniel A. Haber +16 more
TL;DR: These findings suggest that one of these, HKI-272, may prove highly effective in the treatment of EGFR-mutant NSCLCs, including tumors that have become resistant to gefitinib or erlotinib.
Journal ArticleDOI
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
Daphne W. Bell,Thomas J. Lynch,Sara M. Haserlat,Patricia L. Harris,Ross A. Okimoto,Brian W. Brannigan,Dennis C. Sgroi,Beth Muir,Markus J. Riemenschneider,Renee Iacona,Annetta D. Krebs,David H. Johnson,Giuseppe Giaccone,Roy S. Herbst,Christian Manegold,Masahiro Fukuoka,Mark G. Kris,José Baselga,Judith S. Ochs,Daniel A. Haber +19 more
TL;DR: EGFR mutations and, to a lesser extent, amplification appear to identify distinct subsets of NSCLC with an increased response to gefitinib, and the combination of gefithinib with chemotherapy does not improve survival in patients with these molecular markers.